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'e semistable chelate manganese (Mn) dipyridoxyl diphosphate (MnDPDP, mangafodipir), previously used as an intravenous
(i.v.) contrast agent (Teslascan™, GE Healthcare) for Mn-ion-enhanced MRI (MEMRI), should be reappraised for clinical use
but now as a diagnostic drug with cytoprotective properties. Approved for imaging of the liver and pancreas, MnDPDP
enhances contrast also in other targets such as the heart, kidney, glandular tissue, and potentially retina and brain. Trans-
metallation releases paramagnetic Mn2+ for cellular uptake in competition with calcium (Ca2+), and intracellular (IC)
macromolecular Mn2+ adducts lower myocardial T1 to midway between native values and values obtained with gadolinium
(Gd3+). What is essential is that T1 mapping and, to a lesser degree, T1 weighted imaging enable quantification of viability at a
cellular or even molecular level. IC Mn2+ retention for hours provides delayed imaging as another advantage. Examples in
humans include quantitative imaging of cardiomyocyte remodeling and of Ca2+ channel activity, capabilities beyond the scope
of Gd3+ based or native MRI. In addition, MnDPDP and the metabolite Mn dipyridoxyl diethyl-diamine (MnPLED) act as
catalytic antioxidants enabling prevention and treatment of oxidative stress caused by tissue injury and inflammation. Tested
applications in humans include protection of normal cells during chemotherapy of cancer and, potentially, of ischemic tissues
during reperfusion. 'eragnostic use combining therapy with delayed imaging remains to be explored. 'is review updates
MnDPDP and its clinical potential with emphasis on the working mode of an exquisite chelate in the diagnosis of heart disease
and in the treatment of oxidative stress.
1. Background
MRI is an imaging modality which in its native form pro-
duces important diagnostic information with purely in-
strument-based techniques [1]. Diagnostic routine on the
other hand commonly relies upon the use of intravenous
(i.v.), extracellular (EC) contrast agents containing gadoli-
nium (Gd). At present, new contrast agent free (native)
techniques are advancing into clinical practice whereas a
strong standing of Gd agents seems reaffirmed after linear
and semistable chelates were discarded and by paying at-
tention to kidney function [2].
Still, there is a demand for new contrast enhancing
techniques with properties beyond the scope of both native
and Gd basedMRI. Especially, there is a high need for agents
that enable imaging and quantification of tissue viability at a
cellular or close to molecular level. In addition to ensuring
efficacy and safety, preferred new agents should be able to
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improve upon the treatment of patients undergoing diag-
nostic imaging. In retrospect, such an agent, manganese
(Mn) dipyridoxyl diphosphate (MnDPDP), has already been
available but vanished before its potential was recognized by
the imaging community.
Paramagnetic Mn2+ was the first metal ion studied for
contrast enhancement in MRI [3], but fear of cardiotox-
icity and rapid progress of Gd agents restrained the de-
velopment of Mn-ion-enhanced MRI (MEMRI) [4, 5]. As a
consequence, MnDPDP (Teslascan™, GEHealthcare, Oslo,
Norway) became the only i.v. Mn agent for human use
(Figure 1) approved for imaging of liver and pancreas
[6, 7]. After a decade low product earning led to cessation
of marketing (USA 2003) or direct market withdrawal
(Europe 2011). At that time intracellular (IC) Mn2+ was
recognized as an excellent biomarker of cellular events in
various tissues and organs including heart and brain, but
mainly in animals [8–15] and only partly in humans
[16–19]. In parallel, human studies of MnDPDP and its key
metabolite MnPLED (Mn dipyridoxyl diethyl-diamine) as
small molecular catalytic antioxidants controlling reactive
oxygen and nitrogen species (ROS, RNS) were in an early
phase [20–25].
'e aims of the present review are twofold: to focus on a
multifunctional chelate with highly differing functions and
mechanisms (basic properties) and with early examples from
human use to indicate its future possibilities in MEMRI and
therapy (application in humans).
2. Basic Properties
'e behavior of MnDPDP as chelated prodrug in medical
biology represents a blend of disciplines, ranging from
physics and chemistry to pharmacokinetics and physiology
in health and disease. From traversing these fields, come the
basics of MRI and of antioxidant treatment. In spite of an
inherent complexity, interactions between multiple factors
seem mostly fortuitous.
2.1. Physics and Chemistry: In Vitro and In Vivo Factors.
MnDPDP (mangafodipir) is a hexadentate and linear chelate
in which a dimer of vitamin B6 (pyridoxal phosphate) forms
a metal binding pocket (Figure 2). In this site Mn2+ shares 5
unpaired electrons with 4 oxygen and 2 nitrogen atoms of
DPDP (fodipir) and may undergo reversible one-electron
oxidation-reduction [26–28]. 'e 5 unpaired electrons of
Mn2+ yield a strong magnetic moment (5.9 BM (Bohr
Magnetom)) while Mn3+ with 4 is weaker (4.9 BM) and
gadolinium (Gd3+) with 7 is considerably stronger (7.6 BM).
Electron spin resonance (ESR) time is longer and more
optimal with Mn2+ and Gd3+ (10−8–10−9 s) than with Mn3+
(10−10–10−12 s). 'e in vitromolar longitudinal relaxivity (r1)
is 4 times higher with MnCl2 than MnDPDP.
A prerequisite for diverse functions of MnDPDP and
MnPLED is a chelator being able to release and bind bio-
logically active metal ions in a highly hierarchic manner
(Figure 2). Accordingly, with DPDP and PLED the log
conditional stability constants [27], a main index of metal-
chelator affinities, for Mn2+ are well above those of calcium
(Ca2+) and magnesium (Mg2+) but also well below those of
zinc (Zn2+) and of copper (Cu2+) and far below those of iron
(Fe3+). Accordingly, in tissue compartments MnDPDP and
MnPLED undergo successive transmetallation steps
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Figure 1: MnDPDP: T1 weighted image (T1WI) of heart and
abdominal organs. Signal intensity (SI) in Mn2+-enhanced tissue
increases from spleen to liver. Imaging 60min after i.v. infusion of
MnDPDP 5 μmol/kg in a patient with a recent acute myocardial
infarction (AMI) located to left ventricular (LV) septum (Skjold A,
unpublished data).
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Figure 2: MnDPDP: structure, transmetallation, and stability. In MnDPDP 3 anionic sites are balanced by 3 sodium ions. MW: MnDPDP
∼680Da, MnPLED ∼520Da. Transmetallation mainly by zinc (Zn2+) releases Mn2+. 'e enclosed table presents log conditional stability
constants for metal complexes with DPDP, PLED, HSA (human serum albumin), and EDTA (ethylene-diamine tetra-acetic acid). Log
values for Mn2+ binding to main transport proteins in plasma are also included. Material derived from [26–29].
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depending mainly on chelator-metal affinities (log values)
and only partly on concentrations of Mn2+ and competing
cations [26–29]. Of prime importance is that Mn2+ displaces
Ca2+ from binding to physiological ion channels in the cell
membrane and to IC storage and release sites.
Zn2+, with log value of 19.0 (16.7) in binding to DPDP
(PLED) and relative abundance in plasma and interstitium,
is a powerful transmetallator of Mn2+ with 15.1 (12.6) and, in
retrospect, also of Gd3+ in gadodiamide with reported 14.9
[30]. With far higher log values, traces of Fe2+ may outstrip
any other endogenous cation from binding to DPDP and
PLED. Accordingly, i.v. administration of MnDPDP in
humans caused a transient fall not only in plasma Zn2+ [29]
but also in serum Fe2+ [6], with bottom reached at 2 hours
and returning to baseline at 24 hours. Furthermore, a
comparison with clinical chelators reveals that the in vitro
log values of FeDPDP (33.5) and FePLED (36.9) [27] are as
high as or even higher than those reported for, respectively,
deferoxamine (31) and deferitazole (33.4) [31].
Like other metal ions, endogenous Mn2+ appears bound,
mainly to large molecules in plasma and cytosol and in
organelles where Mn2+ attains catalytic functions [32–34]. A
model role is shown in mitochondrial superoxide dismutase
(SOD) containing Mn2+-Mn3+ as redox pair in its catalytic
site (MnSOD). Another consequence of macromolecular
binding is an increase in the rotational correlation time
between Mn2+ and protons in water, thereby greatly en-
hancing r1 of potential Mn2+adducts [26].
2.2. Biotransformation in Human Volunteers. According to
a thorough review by Toft et al. [29], i.v. administered
MnDPDP distributes and releases active metabolites in
plasma and interstitium (Figure 3(a)). In one pathway,
µmolar Zn2+ transmetallates 75–80% of Mn2+ in a clinical
dose of MnDPDP (5–10 μmol/kg) for stepwise uptake in
target cells. After bolus injection of 5 and 10 μmol/kg,
about 20% of Mn2+ is released within 2min by µmolar
Zn2+ present in plasma. 'ereafter about 50% is released
in a delayed manner by gradually available Zn2+ and
possibly by millimolar Ca2+ and Mg2+ within the inter-
stitial space.
In another pathway, alkaline phosphatase (ALP) in plasma
and microcirculation [29] converts water soluble MnDPDP
(ZnDPDP) via monophosphate MnDPMP (ZnDPMP) to lipid
soluble MnPLED (ZnPLED). Dephosphorylation enables
MnPLED to diffuse across cell membranes and even enter
organelles like mitochondria. 'e 20–25% end product
MnPLED disappears from plasma over 60–90min, whereas
ZnPLED remains detectable up to 8 hours. Elimination from
the body differs between Mn2+ and its ligands [29]. 'e liver
acts as a Mn2+ sink with rapid turnover from plasma and
hepatobiliary excretion, while the chelating moieties undergo
renal elimination.'e administeredMn is recoveredwithin 1-2
hours (urine 25%), few days (feces 50–60%), and weeks (feces).
2.3. Cell Mn2+ Uptake and Competition with Ca2+. Mn2+ is a
most potent stalker of Ca2+, conductor of both cell function
and energy metabolism. Hence a graded Mn2+ uptake and
retention in cardiomyocytes and other excitable cells
(Figure 3(b)) mirror the activity of Ca2+ transporters and IC
ligands to which Mn2+ has a higher affinity [8, 9, 12, 35–37].
Mn2+ entry into target cells like cardiomyocytes occurs
predominantly via voltage dependent L-type Ca2+ channels
that open briefly during depolarization [35]. Transient re-
ceptor potential (TRP) operated Ca2+ (and Na+) channels
[37] and bidirectional Na+/Ca2+ exchangers (NCXs) [36]
may also mediateMn2+ influx or retention, probably more in
injured than normal cardiomyocytes or in myofibroblasts
during repair. Mitochondrial Mn2+ entry is via a Ca2+
uniport and exit from mitochondria and cytosol occurs via
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Figure 3: MnDPDP: metabolism andMn2+ uptake and retention in excitable cells. (a) MnDPDP is metabolized in plasma, microcirculation,
and interstitium by transmetallation, mainly with Zn2+, and by the action of alkaline phosphatase (ALP) before delivering Mn2+ and
MnPLED for cellular uptake. (b)Mn2+ follows Ca2+ and electrochemical gradients into and out of cardiomyocytes. Lipid solubleMnPLED is
able to enter cells as intact agent. IC Mn2+ retention for hours is caused by macromolecular binding, especially in protein-dense mi-
tochondria, and by a slow efflux via bidirectional Na+/Ca2+ exchangers (NCXs). Material derived from [29, 35–37].
Contrast Media & Molecular Imaging 3
NCXs. Neuronal Mn2+ uptake occurs via N-type Ca2+
channels but requires prior transport over the blood-brain-
barrier (BBB) and diffusion via cerebrospinal fluid [14–16].
Divalent metal ion transporters [38] are active in longer term
cell exchange of Mn2+.
'e use of Mn2+ as a Ca2+ analog to study normal
physiology and contrast enhancement in the animal heart
and brain have been highlighted in reviews not dealt with
here [8, 9, 12–15]. However, repeated notions of MnDPDP
being a cardiotoxic agent still deserve comment [4, 8]. 'us
the high affinity to Ca2+ channels may in theory depress
cardiovascular function during high dose and rapid i.v.
administration of Mn2+-releasing agents. 'is was exem-
plified by Wolf and Baum with MnCl2 in anesthetized an-
imals in the early days of MRI [4].
Later studies by Jynge et al. in isolated buffer-perfused
small animal hearts [8, 39, 40] confirmed that myocardial
Mn content and longitudinal relaxation rate (R1) correlated
positively with perfusate [Mn2+] and negatively with left
ventricular (LV) developed pressure (LVDP); i.e., high dose
Mn2+ acts as cardiodepressor. Importantly, with perfusate
[Mn2+] below 30 μM, LVDP was not affected but still tissue
Mn content rose 5 times and R1 2.5 times; i.e., there is a wide
margin for diagnostic efficacy without cardiodepression.
Since interstitial [Mn2+] after clinical doses of MnDPDP in
humans is probably less than 1–5 μM [41] and, in non-
medicated conscious dogs, high plasma [Mn2+] may activate
adrenal release of catecholamines [8], negative inotropy and
hypotension will hardly occur in humans. 'is is also
confirmed by broad clinical experience [6, 7, 17–19, 22–25].
2.4. Safety and Brain Accumulation. MnDPDP has an about
10 times higher safety margin than MnCl2 reflecting a more
gradual release of Mn2+ [8]. In offspring of rats both agents
produced skeletal defects related to Mn only [42]. Mn2+-
releasing agents are thus contraindicated in early pregnancy
and preferably in patients with pheochromocytoma. In
humans, mild transient side effects mediated by nitric oxide
(NO) [20, 43] like flushing, occasional headache, and mild
diarrhoea are observed during high dose infusion or rapid
injection of MnDPDP [6].
In the adult human body, the Mn content, 10–20mg
(182–364 μmol) [32, 33], is in the order of an imaging dose.
Still transient accumulation in most tissues seems to be well
tolerated. An important exception is the brain where a
transient and limitedMn2+ uptake may become a safe tool in
functional MRI while a persistent Mn elevation in basal
ganglia may induce oxidative injuries. Also Parkinson-like
symptoms are feared outcomes from long term exposure to
Mn metal whether being environmental, following total
parenteral nutrition, or being caused by liver failure
[33, 44, 45]. Importantly, with MnDPDP, single doses up to
25 μmol/kg were applied in phase II trials without reported
signs of Parkinsonism [6], and based on the success with
MEMRI for study of brain physiology in animals [14, 15]
Reich and Koretsky are exploring the possibility of using
MnDPDP to image neuronal activity and neural tracts in
patients with multiple sclerosis [46]. However, Sudarshana
et al. recently reported [47] that i.v. infusion of a standard
imaging dose (5 μmol/kg) of MnDPDP in healthy human
volunteers raised signal intensity (SI) in exocrine glands in
the head and neck, in the choroid plexus, and in the anterior
pituitary gland but not beyond the intact BBB.
2.5. MEMRI and Contrast Enhancement. MR properties of
IC Mn2+, as the agent that ultimately shortens longitudinal
relaxation time (T1 � 1/R1) but to a lesser degree transversal
relaxation time (T2 �1/R2) of excited protons, have been
studied mostly with use of MnCl2 as Mn2+-delivering agent.
Main mechanisms influencing efficacy of Mn2+ enhance-
ment in a highly excitable tissue like the LV myocardium
have been comprehensively analyzed by Seland et al., Hu
et al., and Bruvold [48–50]. Using relaxography to examine
small animal hearts, mostly additive factors related to T1
behavior, R1-Mn relationships, macromolecules, and field
dependence were studied.
2.5.1. Monoexponential T1 Relaxation. In the rat heart, a
high transmembrane water exchange rate (∼10 s−1) caused
tissue T1 relaxation, representing the sum of IC and ECwater
protons, to becomemonoexponential. Only after an extreme
Mn2+ overload was a second, probably mitochondrial, T1
peak disclosed.
2.5.2. Correlation between R1 and Mn Content. A linear
correlation was found between tissue R1 and Mn content up
to about 10 times normal, i.e., from about 45 to about
500 μmol/kg dry wt. 'is makes R1 a reliable parameter of
Mn2+ uptake and cell function whereas MEMRI of mito-
chondria, otherwise an exciting target, becomes less likely
without supplementary MR techniques [48, 50]. As ex-
pected, the about one order of magnitude higher R1 of bound
vs. freeMn2+makesMEMRI possible with a low µmolar dose
of a Mn2+-releasing agent.
2.5.3. Magnetic Dispersion and Resolution: Low vs. High Field
Imaging. A limitation is that magnetic dispersion above
0.2–0.5 Tesla (T) [24] reduced tissue r1 (s−1·mM−1) from 40–50
at 0.5T, to 30–35 at 2.35T, and to 20–25 at 7T [48, 50].
Conversely, compensating for a reduction in r1 ofMn2+ adducts
at higher fields, the signal to noise ratio (SNR) in T1 weighted
images (T1WI) increases by at least one order of magnitude.
Furthermore, the scale for measuring tissue T1 expanded by
about 30% (native gain) and 40% (Mn2+-enhanced gain) when
raising the field strength from 0.5T to 7.0T [26, 50].
Taken together, MEMRI with IC Mn2+ adducts can be
applied for both low (0.5–1.5 T) and high field (3.0–7.0 T)
imaging. In the heart, a further advantage is that MEMRI
may comply with and improve upon recent and impressive
achievements in native T1-based methods [51, 52].
2.5.4. MEMRI vs. Gd-Based MRI. 'e efficacy of MEMRI is,
as expected, also highly influenced by physiologic and
pharmacokinetic factors which differ fromGd basedMRI. In
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theory, IC Mn2+ uptake requires an active metabolism and
function and requires that healthy cells retain Mn2+ by
strong IC binding and slow efflux. Contrary to this, EC Gd
agents accumulate briefly within the interstitial, including
disrupted IC, water phase. Consequently, when measuring
myocardial infarct size (IS) in rats with permanent coronary
artery ligation (Figure 4), IC Mn2+ adducts lower T1 mainly
in viable cardiomyocytes while Gd-complexes do so in dead
or severely injured tissue (Bruvold M, Seland JG, Jynge P,
unpublished material).
2.6. Tissue Protection in Oxidative Stress. Following a side
track from contrast agent research into the field of “oxidative,”
i.e., combined oxidative-nitrosative, stress and antioxidants
[53–55], Asplund et al. discovered that MnDPDP and
MnPLED dilated arteries [20] by mimicking MnSOD, with
the proposed mechanism that suppression of superoxide
preserved endothelial derived NO for activation of adenylate
cyclase and cyclic GMP thereby relaxing vascular smooth
muscle cells [43]. 'ereafter, electron paramagnetic reso-
nance (EPR) spectroscopy with MnDPDP and MnPLED [21]
added to an in vitro superoxide-generating (xanthine oxidase)
reaction proved that they mimic MnSOD [34] with a half
maximal response concentration (EC50) of 5–10 μM, a highly
relevant plasma level in humans [29]. MnSOD inactivates
superoxide (O−2 ) leaking from the electron chain by instant
dismutation to hydrogen peroxide (H2O2) and O2. Zn-ligands
were without SOD activity.
Experimental data indicate that both ECMnDPDP and IC
MnPLED can be characterized as small molecular enzyme
mimetics endowed with catalytic antioxidant properties
(Figure 5). In acute or subacute conditions of oxidative stress
and inflammation, they seemingly act in either of twoways: by
supplementing SOD activity in plasma and IC and by binding
prooxidant metals like Cu+ and Fe2+ which leak from IC sites
[34, 56–59]. MnDPDP and MnPLED may thereby improve
the balance between salient (low-level) and damaging (high-
level) ROS-RNS: by preserving NO and hydrogen peroxide
for cell signaling [53, 54, 59] and by inhibiting release of
superoxide, hydroxyl (OH), and peroxynitrite (ONOO−)
[43, 55, 56, 59]. Other secondary mechanisms may include
stabilization of lysosomes and mitochondria [60, 61]. Alto-
gether, these properties make MnDPDP a promising drug
delaying tissue injury and inhibiting inflammatory responses.
A further implication of strong chelator binding of Fe2+,
besides inhibiting oxidative stress in severe inflammation, is
an apparent potential to slow replication of rapidly dividing
malignant cells [58, 62] and microorganisms [63].
In preclinical studies, MnDPDP and/or MnPLED pro-
vided significant cytoprotection in chemotherapy of cancer
[62, 64, 65], liver failure during paracetamol poisoning [66],
the heart and liver during reoxygenation/reperfusion after
hypoxia/ischemia [10, 21, 67], and graft protection in
transplantation of liver [68]. In AMI in pigs (Figure 6(a)),
MnPLED, but not MnDPDP, ameliorated ROS-RNS
inflicted reperfusion injury, thereby reducing infarct size by
55%, whereas both agents prevented arrhythmias [10]. 'ese
findings imply that MnPLED accessed mitochondrial sites
critical for cell survival [61] and that MnDPDP may have
acted at the cell membrane level.
Radiation and anticancer drugs produce ROS-RNS [64, 65,
69, 70], and preclinical studies have shown that MnDPDP and/
or MnPLED may protect nerve cells, leukocytes, lymphocytes,
and cardiomyocytes against toxicity of anticancer drugs
(anthracyclines, taxanes, and platinum agents) apparently
without loss of anticancer activity [24, 58, 59, 64, 65]. In mice,
MnPLED preserved myocardial function (Figure 6(b)) during
ex vivo exposure to doxorubicin, and MnDPDP tended to
enhance in vivo tumor reduction (Figure 6(c)) by the same
agent [58].
3. MEMRI in Humans
As amply documented in animals and partly confirmed in
humans, MEMRI enhances tissue contrast by Mn2+ uptake
and retention in excitable cells in liver, pancreas, kidney
cortex and medulla, myocardium, endocrine and exocrine
glands, and potentially retina and brain [4, 8–19, 39, 40].
With MnDPDP, preclinical studies were frequent prior to or
just after the millenium shift, and readers are referred to
comprehensive reviews from that time [8, 9, 11, 13, 16, 39,
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Figure 4: Dual contrast imaging with IC Mn and EC Gd in infarcted rat myocardium. Rats with permanently ligated left coronary artery
underwent single session cardiac MRI at 7.0T. 'e figure displays T1 maps of LV myocardium: Native; Mn (MnCl2 infusion (25μmol/kg)); and
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reactions attacking most cell constituents.'e strategic position of MnDPDP/MnPLED as direct (MnSODmimetic) and indirect (Fe2+/Cu+
chelation) catalytic antioxidants is indicated. Material derived from [34, 43, 53–59]. ·O2−, superoxide; H2O2, hydrogen peroxide;·OH,
hydroxyl radical; NO·, nitric oxide; ONOO−, peroxynitrite; NOS, nitric oxide synthase; MnSOD, mitochondrial SOD; CAT, catalase; GPx,
glutathion peroxidase; NAC, N-acetyl-cysteine; scavengers, antioxidants consumed by ROS-RNS and chain reactants in a one-to-one
manner.
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40]. In patients, MnDPDP, i.e., Teslascan™, has been suc-
cessfully applied for diagnostic imaging of diseases in liver
and pancreas where it demonstrated efficacy in detecting
tumor lesions including metastatic disease [7]. Off-label use
has mainly included cardiac imaging in human volunteers
[16–18, 71] and in patients with ischemic cardiomyopathy
[19, 72–74]. 'ese early examples in MEMRI are detailed as
follows.
3.1. T1 (R1) Mapping of Myocardium with MnDPDP. In
studies by Skjold et al., T1 mapping and T1 weighted imaging
(T1WI) were applied to short axis slices of LV myocardium
(Figure 7) before and after i.v. infusion of MnDPDP (range
5–15 μmol/kg) [17–19, 74]. T1 was measured at 1.5 T (Siemens
Magnetom Symphony) by use of an inversion recovery (IR)
technique [75, 76] with an IR turbo fast low-angle shot
(FLASH) sequence and inversion times (TI) ranging from 90
to 5000ms. Mean values from multiple regions of interest
(ROIs) were processed into one mean T1 (R1) value repre-
senting each of 16–24 transmural LV sectors within a myo-
cardial 8mm thick slice. In healthy volunteers (N� 25) mean
values of native T1 in LV cavitary blood (∼1540ms) were
similar to and in LV myocardium (∼1020ms) 7% higher than
those reported in a more representative reference population
(N� 342) for native T1 mapping at 1.5 T [77].
3.2. Dose-Response and Mn2+ Retention. In human volun-
teers, as measured by Wang et al. [16], there is an ascending
signal intensity (SI) in T1WI from minimal in spleen to
maximal in kidney cortex, pancreas, and liver following
imaging doses (5–10 μmol/kg) of MnDPDP. In a similar
study Skjold et al. [17] assessed dose-responses in liver and
left ventricular LV myocardium (Figure 8) with MnDPDP
(5, 10, 15 μmol/kg) administered outside magnet and in-
termittent recording of R1 over 24 hours.
Peak gains in R1 (ΔR1) above the native level were 35%,
40%, and 44% in LV myocardium whereas ΔR1 values were
3–6 times higher in liver. Myocardial R1 was stable for up to
3-4 hours, and still after 24 hours half of ΔR1 remained. In
comparison, myocardial ΔR1 was considerably below that
reported after injection (150 μmol/kg) of gadopentetate
dimeglumine (30%–74% at 2–20min) [76] but moderately
above that after infusion (5 μmol/kg) of MnCl2 (23%) [78].
In LV myocardium, an optimal dose of MnDPDP
(5–10 μmol/kg) lowered T1 to midway (∼725ms) between
native values (1020ms) and reported Gd-enhanced values
(350–550ms) [76]. Importantly, delayed MEMRI, highly
feasible within 3-4 hours, provides an advantage for exploi-
tation in patient turnover, in screening of viability, and po-
tentially in theragnostic use ofMnDPDP. In liver, a stable time
window was shorter, 1-2 hours. 'e high tissue R1, however,
makes it possible to quantify liver function and viability by a
dose far lower than 5–10 μmol/kg.
3.3. Analysis ofMn2+Uptake. Myocardial Mn2+uptake from
MnDPDP was monitored by continuous online recording
of R1 in healthy young adults [18]. With the same dose
(5 μmol/kg), duration of infusion (Figure 9) presented
different profiles for ΔR1 and Mn2+ uptake, biphasic
(5 min) or linear (30min). On the other hand, ΔR1 over
40min did not differ between infusion groups (5 min,
0.32 s−1; 30min, 0.35 s−1).
When a tracer kinetic model, based on cell influx of
Mn2+ from an assumedly reversible (EC) into a largely ir-
reversible (IC) compartment [79], was applied to the R1
curves, an unidirectional influx constant for Mn2+ (Ki) was
measured as an index of Ca2+ channel activity. As revealed in
kinetic (Patlak) plots, the resulting Ki values (arbitrary units)
were identical in the two infusion groups, 5min (5.73) and
30min (5.72). An attempt to measure tissue fraction of the
Mn2+-donating compartment, i.e., the EC volume (ECV),
revealed results far from an expected 25% level.
With adjustment of infusion time measurements of Ki
and possibly of ECV, the latter a hallmark of Gd-based MRI
[1, 80–82], may become exquisite tools in clinical physiology.
It is also attractive to assess myocardial L-type Ca2+ channel
activity [35], with contribution by other Ca2+ transporters
[36, 37] in disease. Interestingly, the utility of MnDPDP in
tracking Ca2+ channel activity has been confirmed in a
meticulous study of retinal function in light- vs. dark-
adapted rats [83].
3.4. Detection of Myocardial Ischemia by Stress Testing. In
animals, MEMRI can detect myocardial ischemia on its
own [9, 40] by revealing diminished Mn2+ uptake and ΔR1
in an ischemic region. Detection is strengthened, how-
ever, by infusion of the β-adrenergic agonist dobutamine
which enhances inotropy and Mn2+ uptake in non-
ischemic remote regions. Efficacy of MEMRI in dobut-
amine testing requires highly mobile Mn2+ in plasma and
interstitium, as was first demonstrated by Hu and
Koretsky with MnCl2 in rats [12] and later confirmed by
Eriksson and Johansson with a low affinity Mn-chelate in
pigs [84]. With MnDPDP, however, Mn2+ release is too
slow as documented by Amundsen et al. in human vol-
unteers [71]. Hence, infusion of MnDPDP (5 μmol/kg in
5min) during dobutamine stress (10min) did not raise
myocardial R1 above the rest level.
Interestingly, native T1 mapping in patients with coronary
artery disease [52] has shown that increases in myocardial
blood volume (MBV) during vasodilation by adenosine,
minimal in infarcted vs. maximal in remote regions, were
paralleled by transient increases in T1 (0.2% vs. 6.2%). With
infusion of adenosine in due time after MnDPDP infusion, an
infarct-to-remote T1 gradient may be no less. Stress testing
with adenosine after myocardial Mn2+ enhancement with
MnDPDP may thus be an interesting option to pursue.
3.5. Cardiac Injury and Repair in Patients. Clinical reports
with MnDPDP or other Mn2+-releasing agents concern
cardiac remodeling following a previous AMI [19, 72–74]. In
2003, a congress abstract from Abolmaali et al. [72] reported
that MnDPDP (10 μmol/kg) reduced LV myocardial T1 at
1.5 T, from 550ms to 450ms in healthy volunteers (n� 9)
and from 815ms to 630ms in patients with impending heart
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Figure 7: MnDPDP: cardiac MEMRI in a healthy human volunteer [17]. Short axis T1WI and R1 maps before (native) and 60min after i.v.
infusion of MnDPDP 5 μmol/kg are presented. Imaging at 1.5 T. Mean T1 values of 16 sectors were before MnDPDP 1030ms and after
MnDPDP 725ms (reproduced with permission from J Magn Reson Imaging).
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Figure 8: MnDPDP: dose-response and Mn2+ uptake/retention [17]. R1 was measured at 1.5T in liver and LV myocardium before and after
MnDPDP (5, 10, or 15μmol/kg) administered outsidemagnet.ΔR1 values are displayed (reproduced with permission from JMagn Reson Imaging).
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Figure 9: MnDPDP: myocardial Mn2+ uptake in healthy human volunteers [18]. MnDPDP 5 μmol/kg was administered i.v. inside magnet
with infusion time of 5min (n� 5) or 30min (n� 5). R1 values obtained at 1.5 Tover 40min after start of infusion were converted to tissue
[Mn2+] in arbitrary units (a.u.). ΔR1 values were as follows: 5min, 0.32 s−1; 30min, 0.35 s−1 (reproduced with permission from JMagn Reson
Imaging).
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failure (n� 7). Unfortunately, these early data were not
presented in a complete paper.
Present MRI techniques to describe the complex path-
ophysiology of cardiac remodeling [85–87] are based on
signs of edema and fibrosis by delayed contrast enhancement
with EC Gd agents or by native T1 mapping and detection of
deficient contractile function by cine-MRI [1, 5, 80–82]. In
2007 Skjold et al. [19] applied MnDPDP to measure sector-
wise myocardial viability by R1 and systolic wall thickening
(SWT) in patients 3–12 weeks after AMI treated with pri-
mary Percutaneous Coronary Intervention (pPCI). Ten
patients were examined by dual imaging, i.e., before and
after i.v. infusion (5min) of MnDPDP (5 μmol/kg). T1WI
after MnDPDP (Figure 10) demarcated infarcts in 4 patients
only but revealed increase in remote wall thickening in 9.
Importantly, in these 9 patients sectorial LV maps of R1 and
SWT showed identical directions of growing infarct-to-re-
mote gradients. Mn2+-uptake was biphasic in remote sectors
but monophasic and smaller in the infarcted sectors. In one
patient no change from normal appeared, and confirmed
clinical indices of myocardial salvage.
A limitation to the above technique is the lack of finer details
in R1 distribution since only a single mean R1 value represented
each sector and more detailed R1 guided colour coding was not
applied. Still, the accumulated data from all patients and sectors
showed that SWT (range 0–5mm) correlated significantly with
both native R1 and R1 after MnDPDP. Moreover, infarct-to-
remote R1 gradients (Figure 11(a)) were significant both before,
0.87–0.96 s−1 (ΔR1 0.09 s−1), and after, 1.11–1.35 s−1 (ΔR1
0.24 s−1), MnDPDP. 'ese findings, as also presented in a
T1–SWT diagram (Figure 11(b)), illustrate in a quantitative
manner parallel but supplementary aspects ofmyocardial injury
and remodeling. While native T1 maps present overall tissue
conditions rather evenly [1, 81, 82] with main emphasis on EC
events,T1maps afterMn2+ enhancement encompass conditions
in the major IC compartment. Accordingly, native MRI reflects
edema plus fibrosis whereasMEMRImainly reveals energy state
and Ca2+ control in cardiomyocytes.
R1 elevation in revascularized infarct sectors with assum-
edly dead tissue (Figures 10 and 11) seemed a puzzling finding.
Partial elevation of R1 in the infarct, as also observed in rat
hearts (Figure 4), may, besides partial volume effects andMn2+
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Figure 10:MnDPDP: myocardial remodeling in a patient examined 3 weeks after AMI treated with pPCI [19]. One hour after i.v. infusion of
MnDPDP (5 μmol/kg, 5min) T1WI shows a transmural infarct in the LV lateral wall and an apparent thickening of remote myocardium. LV
maps of SWT (mm) and of R1 (s−1) show parallel directions of rising values from the infarct towards remote sectors. Myocardial Mn2+
uptake (arbitrary units (a.u.)) over 30min is biphasic in remote sectors and monophasic and smaller in the infarct. LV ejection fraction
(LVEF): 48%. Reproduced with permission from J Magn Reson Imaging.
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uptake in scattered live cardiomyocytes, be caused by inter-
stitial Mn2+ binding to connective tissue macromolecules.
Another explanation is that Mn2+ may enter proliferating and
Ca2+ conducting myofibroblasts which can uphold tensile
strength and possess semicontractive properties in infarcted
tissue [36, 37, 85–87]. Without delving into further mecha-
nisms,mean sectorialKi values forMn2+ influx (arbitrary units)
of 6.34 (remote) and 5.34 (infarct) and alsomean sectorial ECV
values of 25.8% (remote) and 35.1% (infarct) as reported by
Skjold [74] may be consistent with active or hyperactive car-
diomyocytes vs. tissue in extensive repair [85, 87].
Altogether, although small the study Skjold et al. provides a
snapshot of how MEMRI might be exploited in the human
heart. Both single imaging (MEMRI delayed or online) and dual
imaging (native MRI+online MEMRI) may become attractive
tools for an in-depth analysis of myocardial pathophysiology,
not least when combined with more recently developed map-
ping techniques.
3.6.ExperiencewithDEMRIplusMEMRI. In 2014, Matsuura
et al. [73] reported dual contrast imaging in patients (N= 5)
with ischemic cardiomyopathy using delayed enhancement
MRI (DEMRI) with gadopentetate dimeglumine to be
followed by MEMRI with use of EVP1001. 'e latter is a
rapid Mn2+-releasing gluconate salt supplemented with
Ca2+ (SeeMore™, Eagle Vision Pharmaceuticals, USA). 'e
DEMRI, infarct plus peri-infarct (PIR), region and the
infarcted MEMRI region measured by T1 mapping at 3.0 T
revealed these volumes: DEMRI 34%, MEMRI 14%, and by
subtraction PIR 20%. However, being effective in detecting
the PIR for potential revascularization, the reported pro-
cedure required administering two contrast agents in two
separate imaging sessions.
3.7. Recent Studies of MEMRI with MnDPDP in Animals.
Two recent reports from in vivo rats deserve comment as
they apply current techniques to provide up-to-date infor-
mation on MnDPDP as a biomarker of widely differing
tissue injuries.
In 2018, Spath et al. published an in vivo rat heart study
[88] with measurement of myocardial infarct size (IS) 3 and
12 weeks after AMI. In introductory experiments, the T1
reducing capacity of EVP1001 (22 μmol/kg) and MnCl2
(22 μmol/kg) in normal myocardium at 7.0 T was twice that
of MnDPDP (44 μmol/kg). Still, AMI measurements of IS by
use of EVP1001 (n� 6) and MnDPDP (n� 7) were obtained
with equally high accuracy when compared to histology.
DEMRI with gadobenate dimeglumine (500 μmol/kg)
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Figure 11: MnDPDP: myocardial remodeling—sectorial R1 (T1) vs. systolic wall thickening (SWT) [19]. Mapping of SWT and R1 at 1.5 T
was undertaken in 24 sectors of LV myocardium before (native reference) and one hour after i.v. infusion of MnDPDP (5 μmol/kg, 5min).
Data were obtained from 10 patients undergoing remodeling after AMI. (a) Measured values of R1 (s−1) vs. SWT (mm) before and after
MnDPDP. Dotted black lines are drawn at SWT 0 and 5mm; blue and red lines are drawn between mean R1 values at 0 and 5mm SWT. In
spite of large spread in individual R1 values, significant correlations were found between infarct-to-remote directional angles for SWTand R1
both before and after MnDPDP. Figure reproduced with permission from JMagn Reson Imaging. (b) Diagram based on values from (a) but
presented as T1 (ms) vs. SWT (range 0–5mm).'e dotted horizontal lines mark T1 of normal myocardium [17, 18]. T1-SWTcorrelations are
marked by continuous lines. Blue line: native T1 values (1150–1040ms). Red line: T1 values after MnDPDP (900–740ms).
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applied in prior separate experiments was reported as less
accurate than MEMRI in defining IS by including peri-in-
farct edema and fibrosis.
In 2020, Liu et al. [89] reported on the use of MnDPDP
(25 μmol/kg) and MEMRI to predict the therapeutic efficacy
of a vascular disrupting anticancer agent (VDA) in rats with
primary and secondarymalignancies of liver. Tumor-to-liver
contrast at 3.0 T was judged by tissue SI, and results were
closely compared with postmortem microangiography and
histology. VDA-mediated intratumoral necrosis was imaged
by use of gadoterate meglumine (200 μmol/kg).
Important findings (Figure 12) were first that tumor-to-
liver contrast enhancement by MnDPDP was strong in
highly (grade I) and weak in lowly (grade III-IV) differ-
entiated hepatocellular carcinoma (HCC) before treatment.
Secondly, the necrotic responses to the VDA assessed by Gd-
MRI correlated with the grade of differentiation, i.e., major
in high and minor in low grade HCC. 24-hour delay in
imaging after infusion of MnDPDP avoided transient blood
pool effects and improved the contrast between the HCCs
and liver. 'e study confirms that MEMRI with MnDPDP
represents a noninvasive surrogate for biopsy taking in
primary liver cancer.
4. Therapy in Humans
'ree small scale feasibility studies [23−25] and one case
report [22] indicate that MnDPDP may provide clinically
relevant cytoprotection in humans.
4.1. AMI and Reperfusion Injury [25]. With the aim of
preventing reperfusion injury during pPCI, patients sub-
mitted with their first episode of AMI were randomized to
receive 2min i.v. infusion of MnDPDP (2 μmol/kg) or
placebo (NaCl) immediately after angiography but prior to
the reopening of a culprit coronary artery branch. 'e in-
fusions were without side effects. As reported by Karlsson JE
et al., the MnDPDP group revealed an unfavorable distri-
bution of patients (Table 1), fewer intraventricular thrombi,
and a trend towardsmore rapid reversal of ECG changes, but
the remaining results did not reveal differences between
groups. 'us, a tendency to potential benefit in few patients
needs confirmation in a larger phase II trial, preferably based
on an improved protocol.
4.2. Chemotherapy of Cancer and Adverse Events (AEs).
MnDPDP has been applied to patients with colorectal ad-
enocarcinoma undergoing repeated treatment cycles with
the platinum derivative oxaliplatin and 5-fluorouracil
[22–24]. Severe adverse events (AEs) of oxaliplatin like
painful acute or chronic peripheral sensory neuropathy
(PSN) and bone marrow depression are closely related to
oxidative stress [24, 62, 65, 66]. Importantly, chronic PSN
may be caused by prooxidant platinum ions (Pt2+) accu-
mulating in pain-conducting dorsal root ganglion cells [24].
4.2.1. Case Report. 'e first patient to receive MnDPDP for
therapy was a young male who received palliation by 14
cycles of oxaliplatin, each supplemented with MnDPDP
HCC grade I HCC grade III
T2WI T1WI MnDPDP T2WI T1WI MnDPDP
Figure 12: Predictive imaging prior to therapy of rat livers with hepatocellular carcinoma (HCC) of high (I) and low (III) grade of
differentiation [89]. MnDPDP raised tumor-to-liver contrast in T1WIs, see arrow, in grade I HCC to the left, but hardly in grade III HCC as
depicted to the right (reproduced with permission from Transl Oncol).
Table 1: 'erapy with MnDPDP: cardioprotective adjunct to pPCI during AMI [25].
Group Ischemia time(min)
TIMI flow grade I
before reflow (patients)
STER
(%) CK-MB (μg/L)
LVEF
(%)
Infarct size
(%)
LV
thrombi
(patients)
Placebo (n� 10) 144 3 of 10 73.1 4850 41.8 32.5 5 of 8
MnDPDP (n� 10) 206 0 of 10 84.3 4730 47.7 26.2 1 of 10
p value 0.04 0.07 0.08 0.75 0.50 0.62 0.02
Data are expressed as mean with p values (two-tailed) included. Data in three rows to the right were obtained by the use of late Gd-enhancement MRI
(gadopentetate dimeglumine). TIMI, grading of coronary flow from 0 to 3; STER, STsegment elevation regression at 48 hours; CK-MB, plasma creatine kinase
isoenzyme MB 0–48 hours; LVEF: LV ejection fraction.
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10 μmol/kg, before he succumbed to disease [22]. 'e
regimen went without PSN or reduction in white blood cell
count (WBC), and there was a surprising lowering of pain.
After 8 months, the patient developed a mild hand tremor
as a potential early sign of Parkinsonism. 'en, MRI of the
brain (Figure 13) showed widely distributed Mn deposits
[44, 45] with maximal SI in basal ganglia including dentate
nucleus and globus pallidum. As recently discussed by
Blomlie et al. [90] these basal ganglia sites are also noted for
deposition of Gd3+ [91] indicating a common, possibly
Ca2+ related, pathway for focal brain storage of these
metals.
Mn deposition outside the basal ganglia indicated a most
extensive brain overload due to additive predisposing fac-
tors: a too high total dose vs. time of MnDPDP; a marked
influence by concomitant liver failure; and probably also a
BBB weakened by disease and/or by chemotherapy [33, 44].
'e case illustrates that, with a potential exception for end
stage palliation, there is a need for dose reduction and at-
tention to liver function and BBB integrity in multiple
administrations of MnDPDP.
4.2.2. Prevention of Acute Toxicity. In the first feasibility study
of cytoprotection of normal tissues, Karlsson et al. [23] examined
a small group of patients with locally advanced cancer receiving
3 cycles of oxaliplatin, with each cycle preceded by a low dose of
MnDPDP (2μmol/kg) or saline (placebo). Main significant
findings with MnDPDP compared to placebo were a higher
WBC after these cycles and almost absence of grade II-IV AEs.
In particular, life threatening or severe AEs were only observed
in the placebo group (Figure 14(a)).
4.2.3. Prevention and Reversal of Neurotoxicity. In another
feasibility study, Coriat et al. [24] examined patients with
PSN already detected in prior oxaliplatin cycles who re-
ceived 4–8 further cycles, but now with preinfusion of
MnDPDP (5 μmol/kg). After introducing MnDPDP, the
PSNs became fewer and less severe (Figure 14(b)), indi-
cating both prevention and reversal of nerve toxicity. 'ese
benefits were partly explained by acute MnSOD mimetic
actions. Another likely mechanism implies chelation and
elimination of oxidizing metals including platinum ions
(Pt2+) released from oxaliplatin, an interpretation sup-
ported by EPR analysis revealing a Pt2+ affinity to DPDP
close to that of Cu+ [92]. With an accumulated MnDPDP
dose up to 40 μmol/kg over 4 months in Coriat’s study,
plasma Mn (Figure 14(c)) rose gradually without exceeding
normal levels [33]. 'ere were no signs of Parkinsonism or
bone marrow depression.
'e two latter studies indicate that MnDPDP in a low
imaging dose (2–5 μmol/kg) at timely intervals (2–4 weeks)
and with attention to liver function may prevent and reduce
severe AEs in repeated (4–8) cycles of chemotherapy without
causing any undue Mn accumulation as shown in the case
report. 'e studies were too small, however, to indicate any
effect upon tumor growth.
4.3. Experience with a Derivative of MnDPDP.
[Ca4Mn(DPDP)5] (calmangafodipir, PledOx™, Aladote™,
PledPharma AB, Sweden) was developed with the aim of
combining efficacy in therapy with reduced brain Mn2+ uptake
[59]. In a phase II trial, PledOx seemingly prevented oxali-
platin-induced PSN after 3 and 6months of follow-up, but after
Figure 13: BrainMRI in a patient receivingMnDPDP 140μmol/kg over 8 months [22, 90]. MnDPDP (10μmol/kg) was applied as cytoprotective
adjunct to 14 cycles of chemotherapywith oxaliplatin as the primary drug in a patient with cancer of colon.MRI of the brain (1.5T)was undertaken
after the last cycle. Sagittal and parasagittal images (A-B, a-b) were obtained by T1W-FLAIR and descending axial images (C-D, c-d) by T1W-SE.
High SI reflects markedMn deposition in: A-a, corpus callosum (open arrow), mesencephalon (thick white arrow), and pituitary gland (thin white
arrow); B-b, C-c, putamen and globus pallidus (L nucleus lentiformis) and caput nucleus caudatus (N); D-d, cerebellum with nucleus dentatus
(curved white arrow) and brain stem (white angled arrow) (Blomlie V, Jynge P., unpublished images).
12 Contrast Media & Molecular Imaging
9 and 12months, there were no differences between treated and
nontreated groups [93]. In ongoing trials, paracetamol-over-
dose patients are given Aladote as supplement to the standard
antidote N-acetyl-cysteine (NAC), and initial phase I data
indicate suppression of early biomarkers of liver injury [94].
5. Back to the Future
In reappraising principle and agent for diagnostic imaging
MEMRI andMnDPDP provide unique possibilities to quantify
tissue function and viability at a cellular and subcellular level,
with T1 mapping being more effective than T1WI. Adminis-
tration of MnDPDP outside or inside the magnet enables
examinations ranging from screening of heart disease and of
arrhythmias to in-depth studies of cell Ca2+ fluxes and possibly
measurement of ECV. Detailed information about injury,
repair, and remodeling may also be obtained by dual imaging
combining native MRI with MEMRI.
'e above options may benefit from and potentially
improve recent achievements in native MRI. With sharper
delineation of cardiac anatomy, cine imaging and tagging of
regional contractile function are distinct possibilities to
exploit [51]. 'e same applies to myocardial T1 mapping in
general and during adenosine stress to quantify MBV [52] or
to measure perfusion by arterial spin labeling [95]. Hence,
MEMRI with MnDPDP may give comprehensive infor-
mation about myocardial viability, function, and perfusion,
i.e., key indicators predicting the need for invasive coronary
angiography or reducing the need for endomyocardial
biopsies.
Against a future breakthrough speak a renewed position
of Gd based MRI and the greater T1 shortening capacity of
Gd agents compared to MnDPDP. In addition, recent im-
provements in native MRI may question the need for
contrast agents [1, 51, 52, 82]. Notwithstanding, the IC
approach with direct access to cardiomyocytes,
multifunctional properties, and a potential to replace isotope
scanning support a future role of cardiac MEMRI with
MnDPDP. Likewise, quantification of viability is a unique
principle which may be adopted for other organs like liver,
pancreas, kidney, endocrine, and exocrine glands, subjected
to tissue injury and repair.
Of particular advantage is that cytoprotection offered by
MnDPDP may both increase the safety and extend the diag-
nostic applications. A major problem in cardiovascular disease
and in diabetes refers to the use of contrast media in patients
with impaired kidney function. At present, the intravascular,
nanoparticular, and iron oxide-containing compound Fer-
umoxytol, mainly a T2 or T2∗ agent, serves as a safe substitute
for Gd compounds in MRI of kidney [96]. Interestingly, with
transient renal perfusion with MnDPDP including MnPLED
and uptake/retention of paramagnetic Mn2+ in the cortex,
MnDPDPmight become attractive as a safe alternative.What is
essential for safety is conservation of NO, a mediator of
intrarenal perfusion and key to kidney preservation [97]. With
an apparent cortex-to-medulla T1 gradient and long imaging
window [13, 16], MnDPDP might also be effective in imaging
of renal diseases. Altogether, combining imaging with potential
tissue protection, hitherto not tested in the human kidney, may
become an important option to pursue.
Since MnDPDP both images and preserves viable
myocardium, theragnostic use seems a distinct possibility,
for example, in AMI, the post-cardiac-arrest syndrome, and
heart failure with inflammation and oxidative stress. A
particularly important scenario may be its use as cytopro-
tective and diagnostic adjunct to chemotherapy with
anthracyclines [58, 70, 98] which cause both acute and
chronic heart failure at least partly due to production of
ROS-RNS. In spite of limited or no success with scavenging
agents [98], it still seems rational to attack the problem with
a potent catalytic antioxidant acting at both initial and
subsequent steps in a prooxidant cascade. MnDPDP may
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Figure 14: MnDPDP as cytoprotective adjunct to chemotherapy. Patients with advanced cancer of colon were treated with repeated cycles
with oxaliplatin as primary anticancer drug and MnDPDP as adjunct for protection of normal tissues. (a) Adverse events (AEs) [23]. AEs of
grade I (mild), II (moderate), III (severe), and IV (life-threatening) were recorded in 14 patients during 3 therapy cycles with oxaliplatin and
with preinfusion of MnDPDP 2 μmol/kg or saline (placebo). 'ere was a major reduction in AEs grade II-IV with MnDPDP. Also plasma
leukocyte content was maintained at a higher level with MnDPDP (reprinted with permission from Translational Oncology). (b) Peripheral
sensory neuropathy (PSN) [24]. Patients that experienced PSN during previous oxaliplatin cycles were followed for up to 8 further cycles,
each with preinfusion of MnDPDP 5 μmol/kg. In these cycles, MnDPDP gradually reduced the initial severity of PSN (black> dark
gray> light gray) indicating a reversal of the underlying nerve injuries (reprinted with permission from J Clin Invest). (c) Plasma [Mn]
(nmol/L) during therapy with oxaliplatin and MnDPDP [24]. Patients cited in B showed a gradual rise in plasma [Mn] over 8 cycles in 4
months without exceeding normal levels of 10–20 nmol/L [29, 33] (reprinted with permission from J Clin Invest).
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here be given as a cytoprotectant at onset of each treatment
cycle while serving as a contrast agent for delayed imaging
and monitoring of myocardial viability.
A parallel indication concerns the liver in abdominal
cancer. In hepatic failure induced by paracetamol [66, 94] or
by other etiology (hepatitis), low-dose MnDPDP may be-
come both therapeutic drug and biomarker. A further option
is in the transplantation field with imaging and protection of
donor cells and organs as well as of the recipient. Stem cells
in general [99] and pancreatic islets [100] together with
cardiac, liver, and kidney transplants might become likely
candidates.
“Manganese and MRI” reveals a current annual publi-
cation rate of about 100, but with more focus on new and
stable macrocyclic chelates or (nano)particulate matter than
on Mn2+-releasing agents as is required in MEMRI. 'us
Mn2+ apparently substitutes for Gd3+ in novel highly stable
complexes designed for EC, intravascular, or molecular-tar-
geted deliveries [101, 102]. With exception of EVP1001 [73]
MEMRI has not materialized in new i.v. formulations for trial
in humans. Of considerable interest, though, is the recent
indication in animals [103] of efficacy of a miniature dose of a
52Mn tracer with MEMRI-like properties in PETof the brain,
thereby offering promise for functional PET/MRI.
6. Conclusion
Attempts are now made to reposition MnDPDP for diag-
nostic use in both the USA [46] and Europe [104]. With
current insight into its workmode inMEMRI and in treating
conditions of oxidative stress, previous indications are open
for immediate use and new possibilities appear ready for off-
label assessment of a future potential. 'e challenge will be
to develop MEMRI and MnDPDP for use in daily routine
and not only as exciting tools in clinical research. 'orough
clinical trials are thus required.
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